Prestige Brands Holdings

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

PBH reports record fiscal 2023 results, addresses inflation challenges

PBH's strong fiscal 2023 performance was highlighted, but challenges from inflation and foreign currency headwinds were acknowledged. The company is focused on leveraging opportunities for growth and remains committed to its long-term goals.

PBH reports resilient Q1 performance, anticipates high single-digit Q2 growth

PBH's Q1 performance demonstrated resilience with strong sales and margin improvements. While facing challenges in EBITDA and gross margin, the company's strategic focus on brand growth, debt reduction, and share buyback program positions it well for future opportunities. With a reaffirmed full-year outlook and anticipated Q2 growth, PBH remains focused on sustainable growth and financial discipline.

Prestige Brands reports solid Q3 earnings, eyes growth opportunities

Prestige Brands Holdings (PBH) delivered a solid performance in Q3 2023, driven by strong revenue growth, profitability, and strategic financial management.
While facing challenges such as gross margin decline and industry-wide inflationary pressures, the company remains focused on cost management and pricing strategies to sustain growth.
With opportunities for revenue growth, operational efficiency, and strategic planning in fiscal 2024, Prestige Brands is well-positioned for continued success and value creation.

Prestige Brands Holdings reports record fiscal '23 results and outlines growth strategies for fiscal '24

Prestige Brands Holdings delivered strong financial results in fiscal '23, with robust revenue growth and adjusted EPS. The company is focused on maintaining margins, reducing leverage, and capitalizing on growth opportunities in key segments. Management's strategic outlook for fiscal '24 includes revenue projections, EPS targets, and a commitment to disciplined capital allocation.

Prestige Brands Holdings (PBH) surpasses Q1 expectations amidst challenges

PBH's Q1 performance exceeded expectations with strong organic sales growth and improved gross margin despite cost pressures.
While facing challenges from cost increases and debt levels, PBH maintains a solid financial position with strong cash flow.
Opportunities lie in sustained revenue growth, market expansion, and operational efficiency enhancements for PBH in the coming quarters.

Prestige Brands reports robust Q2 results, eyes international growth

Prestige Brands Holdings delivered a solid performance in Q2, driven by strong sales, EPS growth, and debt reduction.
While facing challenges in North America and margin pressure, the company's international growth and e-commerce focus present opportunities for future expansion.
Maintaining a healthy financial position with strong cash flow and reaffirming full-year outlook underscores Prestige Brands' stability and growth potential.
Strategic management of expenses and leveraging brand success will be crucial for sustained growth and profitability in the competitive consumer goods market.

Prestige Brands Holdings reports solid Q3 performance and eyes growth

Prestige Brands Holdings delivered a strong Q3 performance with revenue exceeding expectations and a focus on maintaining market share and brand differentiation.
The company's financial discipline led to debt reduction and healthy free cash flow, while challenges include inventory coverage issues and evaluating M&A opportunities.
Opportunities for growth include exploring potential M&A deals, focusing on long-term financial targets, and capitalizing on international and North American segment growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the North American OTC Healthcare and International OTC Healthcare segments. The North American and International OTC Healthcare segments manage the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

Prestige Consumer Healthcare Inc. (PBH) CEO Ron Lombardi on Q4 2019 Results - Earnings Call Transcript

Prestige Consumer (PBH) posts better-than-expected Q4 results, driven by solid consumption trends. For fiscal 2020, it is on track to reduce debt.

Prestige Consumer (PBH) Q4 Earnings & Sales Beat Estimates

Prestige Consumer's (PBH) Q4 results are likely to be hurt by low inventory levels in the North American and International units.

Soft Inventory to Hurt Prestige Consumer's (PBH) Q4 Earnings

Prestige Consumer Healthcare has a portfolio of leading over-the-counter healthcare brands, many that hold #1 positions in their respective categories.

Prestige Consumer Healthcare: An Immediate Buy Opportunity Of An Overlooked Midcap Company

Prestige Brands (PBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Prestige Brands (PBH) Up 0.5% Since Last Earnings Report?

News for Prestige Brands Holdings Stock (PBH)